A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 1, 2014, Pages 47-54

  Hansen, Karen E ^a   Kleker, Brian ^b   Safdar, Nasia ^a,c   Bartels, Christie M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b KAISER PERMANENTE   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Bone mineral density; Children; Fracture; Glucocorticoid therapy; Meta analysis; Systematic review

Indexed keywords

CALCIUM; DEFLAZACORT; DEXAMETHASONE; GLUCOCORTICOID; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PREDNISOLONE; PREDNISONE; VITAMIN D;

ADOLESCENT; ADULT; BONE DENSITY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; FRACTURE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HUMAN; INCIDENCE; LOW DRUG DOSE; MALE; META ANALYSIS; MORPHOMETRICS; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SPINE FRACTURE; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; DRUG EFFECTS; INFANT; NEWBORN; PRESCHOOL CHILD; RHEUMATIC DISEASES;

ADOLESCENT; BONE DENSITY; CHILD; CHILD, PRESCHOOL; GLUCOCORTICOIDS; HUMANS; INFANT; INFANT, NEWBORN; OSTEOPOROSIS; RHEUMATIC DISEASES;

EID: 84905215727     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.02.002     Document Type: Review

References (32)

1. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000.
2. Chappard D., Legrand E., Basle M.F., Fromont P., Racineux J.L., Rebel A., et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 1996, 11:676-685.
3. Dalle Carbonare L., Arlot M.E., Chavassieux P.M., Roux J.P., Portero N.R., Meunier P.J. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001, 16:97-103.
4. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282.
5. van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
6. Van Staa T.P., Laan R.F., Barton I.P., Cohen S., Reid D.M., Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224-3229.
7. van Staa T.P., Geusens P., Pols H.A., de Laet C., Leufkens H.G., Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005, 98:191-198.
8. Grossman J.M., Gordon R., Ranganath V.K., Deal C., Caplan L., Chen W., et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010, 62:1515-1526.
9. Leonard M.B. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007, 119(Suppl. 2):S166-S174.
10. Gordon C.M., Bachrach L.K., Carpenter T.O., Crabtree N., El-Hajj Fuleihan G., Kutilek S., et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008, 11:43-58.
11. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52:377-384.
12. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. (W64).
13. Del Re AC, Hoyt WT. MAd: Meta-analysis with mean differences. R package version 0.9 ed; 2010.
14. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Software 2010, 36:1-48.
15. R: A language and environment for statistical computing 2008, R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria.
16. Falcini F., Trapani S., Civinini R., Capone A., Ermini M., Bartolozzi G. The primary role of steroids on the osteoporosis in juvenile rheumatoid patients evaluated by dual energy X-ray absorptiometry. J Endocrinol Invest 1996, 19:165-169.
17. Rudge S., Hailwood S., Horne A., Lucas J., Wu F., Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology 2005, 44:813-818.
18. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 2003, 327:557-560.
19. Brik R., Keidar Z., Schapira D., Israel O. Bone mineral density and turnover in children with systemic juvenile chronic arthritis. J Rheumatol 1998, 25:990-992.
20. Celiker R., Bal S., Bakkaloglu A., Ozaydin E., Coskun T., Cetin A., et al. Factors playing a role in the development of decreased bone mineral density in juvenile chronic arthritis. Rheumatol Int 2003, 23:127-129.
21. Kashef S., Saki F., Karamizadeh Z., Kashef M.A. Bone mineral density in children wth systemic lupus erythematosus and juvenile rheumatoid arthritis. Ann Saudi Med 2007, 27:427-431.
22. Ferrara M., Borrelli B., Greco N., Coppola L., Coppola A., Simeone G., et al. Side effects of corticosteroid therapy in children with chronic idiopathic thrombocytopenic purpura. Hematology 2005, 10:401-403.
23. Kim S.D., Cho B.S. Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. Nephron Clin Pract 2006, 102:c81-c87.
24. Bak M., Serdaroglu E., Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatr Nephrol 2006, 21:350-354.
25. Escolar D.M., Hache L.P., Clemens P.R., Cnaan A., McDonald C.M., Viswanathan V., et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011, 77:444-452.
26. Rodd C., Lang B., Ramsay T., Alos N., Huber A.M., Cabral D.A., et al. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res 2012, 64:122-131.
27. Stewart W.A., Acott P.D., Salisbury S.R., Lang B.A. Bone mineral density in juvenile dermatomyositis: assessment using dual x-ray absorptiometry. Arthritis Rheum 2003, 48:2294-2298.
28. van Staa T.P., Cooper C., Leufkens H.G., Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003, 18:913-918.
29. Huber A.M., Gaboury I., Cabral D.A., Lang B., Ni A., Stephure D., et al. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res 2010, 62:516-526.
30. Loftus J., Allen R., Hesp R., David J., Reid D.M., Wright D.J., et al. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort. Pediatrics 1991, 88:428-436.
31. Nakhla M., Scuccimarri R., Duffy K.N., Chedeville G., Campillo S., Duffy C.M., et al. Prevalence of vertebral fractures in children with chronic rheumatic diseases at risk for osteopenia. J Pediatr 2009, 154:438-443.
32. Varonos S., Ansell B.M., Reeve J. Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy. Calcif Tissue Int 1987, 41:75-78.